Evidence map›Paper›PMID 33121316›Full record

ArticleHuman vaccines & immunotherapeutics2021

One year period of invasive pneumococcal disease in children from a tertiary care hospital in Turkey in the post-vaccine era.

Gulnihan Ustundag, Eda Karadag-Oncel, Sebahat Sen-Tas, Ahu Kara-Aksay, Dilek Yilmaz-Ciftdogan, Nisel Yilmaz, Mehmet Ceyhan

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Gulnihan UstundagDivision of Pediatric Infectious Diseases, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.ORCID 0000-0002-6217-1927
Eda Karadag-OncelDivision of Pediatric Infectious Diseases, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
Sebahat Sen-TasDepartment of Microbiology, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
Ahu Kara-AksayDivision of Pediatric Infectious Diseases, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
Dilek Yilmaz-CiftdoganDivision of Pediatric Infectious Diseases, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
Nisel YilmazDepartment of Microbiology, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
Mehmet CeyhanDivision of Pediatric Infectious Diseases, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Izmir University · TRHacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of invasive pneumococcal disease (IPD) has decreased after pneumococcal conjugate vaccine used; however, a breakthrough infection may still be seen after vaccination. In this study, eight pediatric inpatients and nine episodes with IPD in our center were included. Their age and gender, diagnoses, facilitating factors, the status of immunization and the antibiotic resistance of Pneumococci, serotypes of Pneumococci were noted. The isolates were subjected to disc susceptibility tests for penicillin, macrolides, and fluoroquinolones, according to the guidelines of the Clinical and Laboratory Standards Institute. Of the vaccinated seven cases, four of them (57.1%) developed IPD which their serogroups were in vaccine content. It was observed that all four cases in question had an underlying facilitating factor. Pneumococcal antibiotic susceptibility is also crucial. Three of nine isolates (33.4%) were resistant, and one isolate (11.2%) was intermediate susceptible to penicillin. Six of the nine isolates (66.7%) had macrolide resistance in our investigation. Invasive pneumococcal infections with serogroups that exist in pneumococcal conjugate vaccine content may occur in vaccinated individuals.

Indexed as

Anti-Bacterial AgentsPneumococcal InfectionsChildDrug Resistance, BacterialHumansInfantMacrolidesPneumococcal VaccinesSerogroupSerotypingTertiary Care CentersTurkeyAnti-Bacterial AgentsMacrolidesPneumococcal VaccinesChildreninvasive pneumococcal diseasepneumococcal conjugate vaccineserotypestreptococcus pneumoniae

Identifiers

PMID33121316
PMCPMC8078653
OpenAlexW3096097386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.